Clinical Trial: NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Solid Tumor
Study Type: INTERVENTIONAL
Official Title: Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Brief Summary:
The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors.The main question it aims to answer is to find the recommended dose and scheduled for the combination of NEROFE and doxorubicin.Participants will receive weekly doses of NEROFE and doxorubicin.
Read more